BCLI

Brainstorm Cell Therapeutics Inc. (BCLI) | Rumor.io

Brainstorm Cell Therapeutics

BCLI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-10.3M

Social

What share of all stock conversation is about BCLI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 18

The company is under pressure from the ALS community to approve its stem cell treatment, Nurown, with some calling for a hostile takeover of the company.
The FDA's decision to recommend against approval of Nurown has been met with criticism from patients and advocates, who argue that the treatment has shown promise in real-world evidence.
The company's CEO, Chaim Lebovits, has been criticized for his leadership and dedication to the ALS community, with some calling for him to be replaced by a more effective leader.

Generated by AI

Sentiment

Of the messages about BCLI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	22.22%	22.22%	51.79% -14.78
Bearish	0%	77.78%	77.78%	48.21% +14.78

Bullish· May 19

The company has received FDA approval to begin its Phase 3b ALS trial, signaling regulatory alignment and zero obstruction under the current FDA leadership.
BrainStorm Cell Therapeutics has a strong potential for growth, with the possibility of non-dilutive funding through grants, partnerships, and strategic support, which could lead to a run towards $5 and full NASDAQ compliance.
The company's partnership with Nvidia and the use of AI in collaboration with the tech giant could lead to a breakthrough in ALS treatment, making the stock a highly attractive investment opportunity.

Bearish· May 19

$BCLI's stock price has dropped significantly, potentially indicating a large sell-off or a failed attempt to recover.
The company's leadership, specifically Chaim, has been criticized for lacking execution and making unfunded promises, which may undermine investor confidence.
The company's recent funding issues and potential delisting threat could further exacerbate the bearish sentiment surrounding $BCLI.

Generated by AI

Topics

Of the messages about BCLI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	72.59%
Controversies	—	—	—	27.41%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Mar 8

Brainstorm Cell Therapeutics Inc. ($BCLI) reported Q4 2017 earnings, beating estimates by $0.11 EPS.
The company's quarterly earnings results were announced, with a reported EPS of $0.02, beating expectations.
$BCLI stock dropped 16% since the last earnings report, but is expected to report earnings on 3/8 before the open.

Announcements· Jun 6

BrainStorm Cell Therapeutics Inc. ($BCLI) announced an FDA Advisory Committee Meeting to review its NurOwn Biologics License Application on September 27, 2023.
The meeting is scheduled to review the BLA for NurOwn, an investigational mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The PDUFA goal date for the application is December 8, 2023.

Technical Analysis· Nov 22

The stock $BCLI (Brainstorm Cell Therapeutics Inc.) dropped from $12 to $4.34 due to disappointing clinical trial results, but the company is confident in its treatment's potential.
A green candle was forming on the stock's chart before market close on Friday, indicating a possible upward trend.
The company has other studies and testing underway, including phase two trials for multiple sclerosis, which could provide future catalysts for the stock.

Generated by AI

Community

Of the messages about BCLI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	84.62%	87.5%	84.41%
Newcomers	0%	15.38%	12.5%	15.59%

Regulars· Jul 18

The ALS community is applying pressure on the FDA to approve Nurown, and the FDA may cave in due to the community's demands, making Brainstorm Cell Therapeutics a potential billion-dollar company.
Dr. Karussis is making noise, and the board members should immediately replace the CEO to avoid lawsuits and protect the company's interests.
The stock's price drop is largely due to the CEO's incompentence and the lack of institutional investors, making it a lottery ticket with a 90% chance of winning, and some big investors need to come together to do a hostile takeover to save NurOwn.

Newcomers· May 20

The company is actively engaged in a clinical trial agreement with approximately 15 leading clinical partners across the United States, with announcements to be made soon.
The company's partnership with Johns Hopkins, a global leader in research on ALS, is a significant development, and the potential for non-dilutive grants could help the stock reach $2-$2.5.
The shorts are attempting to prevent life-saving treatments from being tested, and the company's progress is hindered by skepticism from past years, but the potential for a letter of intent for production in the US is promising.

Generated by AI

Also Discussed

Investors talking about BCLI also mention

#	Name	Attention
1	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
2	Coya Therapeutics, Inc.COYA	0%new
3	BioLife Solutions Inc.BLFS	0%0
4	NeuroSense Therapeutics Ltd.NRSN	0%0
5	Vericel CorporationVCEL	0%0
6	Clene Inc.CLNN	0%+0
7	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
8	Cytokinetics, IncorporatedCYTK	0.01%+0
9	BioLine RX LtdBLRX	0%0
10	Can-Fite BioPharma Ltd. ADRCANF	0%0

Brainstorm Cell Therapeutics Inc.

Healthcare
Biotechnology

Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing innovative cellular therapies for neurodegenerative diseases. It primarily concentrates on the advancement of its proprietary stem cell-based platform technology, NurOwn, which is designed to treat severe, debilitating conditions like Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's Disease. The technology involves the differentiation of autologous mesenchymal stem cells into cells that secrete neurotrophic factors, which are believed to support nerve growth and survival. In the broader market landscape, Brainstorm Cell Therapeutics plays a crucial role within the biotech sector, which is constantly exploring cutting-edge treatments to meet unmet medical needs. The company's work significantly impacts the healthcare industry by potentially providing new therapeutic options for patients who have limited alternatives. As a member of the biotechnology landscape, Brainstorm's innovations not only have the potential to transform individual lives but also signify advances in regenerative medicine, highlighting the importance of research and development in cellular and molecular therapies.

Website

Location

1325 Avenue of Americas

New York, NY, 10019

United States

Social

What share of all stock conversation is about BCLI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 18

The company is under pressure from the ALS community to approve its stem cell treatment, Nurown, with some calling for a hostile takeover of the company.
The FDA's decision to recommend against approval of Nurown has been met with criticism from patients and advocates, who argue that the treatment has shown promise in real-world evidence.
The company's CEO, Chaim Lebovits, has been criticized for his leadership and dedication to the ALS community, with some calling for him to be replaced by a more effective leader.

Generated by AI

Sentiment

Of the messages about BCLI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	22.22%	22.22%	51.79% -14.78
Bearish	0%	77.78%	77.78%	48.21% +14.78

Bullish· May 19

The company has received FDA approval to begin its Phase 3b ALS trial, signaling regulatory alignment and zero obstruction under the current FDA leadership.
BrainStorm Cell Therapeutics has a strong potential for growth, with the possibility of non-dilutive funding through grants, partnerships, and strategic support, which could lead to a run towards $5 and full NASDAQ compliance.
The company's partnership with Nvidia and the use of AI in collaboration with the tech giant could lead to a breakthrough in ALS treatment, making the stock a highly attractive investment opportunity.

Bearish· May 19

$BCLI's stock price has dropped significantly, potentially indicating a large sell-off or a failed attempt to recover.
The company's leadership, specifically Chaim, has been criticized for lacking execution and making unfunded promises, which may undermine investor confidence.
The company's recent funding issues and potential delisting threat could further exacerbate the bearish sentiment surrounding $BCLI.

Generated by AI

Topics

Of the messages about BCLI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	72.59%
Controversies	—	—	—	27.41%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Mar 8

Brainstorm Cell Therapeutics Inc. ($BCLI) reported Q4 2017 earnings, beating estimates by $0.11 EPS.
The company's quarterly earnings results were announced, with a reported EPS of $0.02, beating expectations.
$BCLI stock dropped 16% since the last earnings report, but is expected to report earnings on 3/8 before the open.

Announcements· Jun 6

BrainStorm Cell Therapeutics Inc. ($BCLI) announced an FDA Advisory Committee Meeting to review its NurOwn Biologics License Application on September 27, 2023.
The meeting is scheduled to review the BLA for NurOwn, an investigational mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The PDUFA goal date for the application is December 8, 2023.

Technical Analysis· Nov 22

The stock $BCLI (Brainstorm Cell Therapeutics Inc.) dropped from $12 to $4.34 due to disappointing clinical trial results, but the company is confident in its treatment's potential.
A green candle was forming on the stock's chart before market close on Friday, indicating a possible upward trend.
The company has other studies and testing underway, including phase two trials for multiple sclerosis, which could provide future catalysts for the stock.

Generated by AI

Community

Of the messages about BCLI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	84.62%	87.5%	84.41%
Newcomers	0%	15.38%	12.5%	15.59%

Regulars· Jul 18

The ALS community is applying pressure on the FDA to approve Nurown, and the FDA may cave in due to the community's demands, making Brainstorm Cell Therapeutics a potential billion-dollar company.
Dr. Karussis is making noise, and the board members should immediately replace the CEO to avoid lawsuits and protect the company's interests.
The stock's price drop is largely due to the CEO's incompentence and the lack of institutional investors, making it a lottery ticket with a 90% chance of winning, and some big investors need to come together to do a hostile takeover to save NurOwn.

Newcomers· May 20

The company is actively engaged in a clinical trial agreement with approximately 15 leading clinical partners across the United States, with announcements to be made soon.
The company's partnership with Johns Hopkins, a global leader in research on ALS, is a significant development, and the potential for non-dilutive grants could help the stock reach $2-$2.5.
The shorts are attempting to prevent life-saving treatments from being tested, and the company's progress is hindered by skepticism from past years, but the potential for a letter of intent for production in the US is promising.

Generated by AI

Brainstorm Cell Therapeutics

Social

Jul 18

Sentiment

Bullish· May 19

Bearish· May 19

Topics

Earnings· Mar 8

Announcements· Jun 6

Technical Analysis· Nov 22

Community

Regulars· Jul 18

Newcomers· May 20

Also Discussed

Brainstorm Cell Therapeutics Inc.

Company Information

Location

Also Discussed

Social

Jul 18

Sentiment

Bullish· May 19

Bearish· May 19

Topics

Earnings· Mar 8

Announcements· Jun 6

Technical Analysis· Nov 22

Community

Regulars· Jul 18

Newcomers· May 20